• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD.

作者信息

Neagu Matei, Coca Daniel, Ong Albert C M

机构信息

University of Sheffield, Sheffield, UK.

University of Sheffield, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

出版信息

Am J Kidney Dis. 2018 Jun;71(6):912-913. doi: 10.1053/j.ajkd.2018.01.052. Epub 2018 Mar 30.

DOI:10.1053/j.ajkd.2018.01.052
PMID:29609977
Abstract
摘要

相似文献

1
Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD.达到终末期肾病的常染色体显性多囊肾病患者的线性和非线性估计肾小球滤过率斜率
Am J Kidney Dis. 2018 Jun;71(6):912-913. doi: 10.1053/j.ajkd.2018.01.052. Epub 2018 Mar 30.
2
In Reply to 'Artificial Intelligence Can Predict GFR Decline During the Course of ADPKD' and 'Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD'.回复《人工智能可预测常染色体显性多囊肾病病程中的肾小球滤过率下降》及《终末期肾病常染色体显性多囊肾病患者的线性和非线性估计肾小球滤过率斜率》
Am J Kidney Dis. 2018 Jun;71(6):913. doi: 10.1053/j.ajkd.2018.02.349. Epub 2018 Mar 30.
3
Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.常染色体显性多囊肾病中的肌酐管状分泌：对肾功能评估方程的横断面和纵向表现的影响。
Am J Kidney Dis. 2013 Sep;62(3):531-40. doi: 10.1053/j.ajkd.2013.03.030. Epub 2013 May 25.
4
[AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: HOW AND WHY SHOULD WE IDENTIFY THE PATIENTS "RAPIDLY PROGRESSING" TO END-STAGE RENAL DISEASE?].[常染色体显性多囊肾病：我们应如何以及为何要识别那些“快速进展”至终末期肾病的患者？]
Rev Med Liege. 2016 Apr;71(4):184-92.
5
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.托伐普坦对不同肾功能水平常染色体显性多囊肾病个体的短期疗效。
Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.
6
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.常染色体显性多囊肾病中肾血流的磁共振测量与疾病进展
Clin J Am Soc Nephrol. 2007 Jan;2(1):112-20. doi: 10.2215/CJN.00910306. Epub 2006 Nov 2.
7
Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.极早发型常染色体显性多囊肾病患者的长期预后
Am J Nephrol. 2016;44(3):171-8. doi: 10.1159/000448695. Epub 2016 Aug 23.
8
The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre.常染色体显性遗传性多囊肾病的自然病程：单中心 30 年经验
QJM. 2013 Jul;106(7):639-46. doi: 10.1093/qjmed/hct082. Epub 2013 Apr 15.
9
Copeptin levels and kidney function in ADPKD: case-control study.常染色体显性多囊肾病中的 copeptin 水平与肾功能：病例对照研究
Clin Nephrol. 2016 Sep;86(9):147-53. doi: 10.5414/CN108894.
10
Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.用胱抑素C估算肾小球滤过率评估常染色体显性多囊肾病早期的肾功能。
PLoS One. 2017 Mar 27;12(3):e0174583. doi: 10.1371/journal.pone.0174583. eCollection 2017.

引用本文的文献

1
Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan.来自英格兰东北部常染色体显性多囊肾病（ADPKD）患者队列使用托伐普坦的结果。
Front Nephrol. 2022 Sep 23;2:984165. doi: 10.3389/fneph.2022.984165. eCollection 2022.
2
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.托伐普坦治疗常染色体显性遗传性多囊肾病的应用进展：代表欧洲肾脏协会遗传性肾脏疾病工作组、欧洲罕见肾脏疾病参考网络和多囊肾病国际组织的共识声明。
Nephrol Dial Transplant. 2022 Apr 25;37(5):825-839. doi: 10.1093/ndt/gfab312.
3
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.托伐普坦治疗对常染色体显性多囊肾病肾功能下降的长期益处建模：使用常染色体显性多囊肾病结局模型的探索性分析
BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5.